215 related articles for article (PubMed ID: 36584674)
1. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
Amodio V; Lamba S; Chilà R; Cattaneo CM; Mussolin B; Corti G; Rospo G; Berrino E; Tripodo C; Pisati F; Bartolini A; Aquilano MC; Marsoni S; Mauri G; Marchiò C; Abrignani S; Di Nicolantonio F; Germano G; Bardelli A
Cancer Cell; 2023 Jan; 41(1):196-209.e5. PubMed ID: 36584674
[TBL] [Abstract][Full Text] [Related]
2. Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer.
Rospo G; Chilà R; Matafora V; Basso V; Lamba S; Bartolini A; Bachi A; Di Nicolantonio F; Mondino A; Germano G; Bardelli A
Genome Med; 2024 Jan; 16(1):15. PubMed ID: 38243308
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
[TBL] [Abstract][Full Text] [Related]
4. Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features.
Berrino E; Aquilano MC; Valtorta E; Amodio V; Germano G; Gusmini M; Gizzi K; Fenocchio E; Sapino A; Marsoni S; Sartore-Bianchi A; Bardelli A; Siena S; Bonoldi E; Marchiò C
Mod Pathol; 2023 Feb; 36(2):100012. PubMed ID: 36853785
[TBL] [Abstract][Full Text] [Related]
5. Impact of DNA mismatch repair proteins deficiency on number and ratio of lymph nodal metastases in colorectal adenocarcinoma.
Zannier F; Angerilli V; Spolverato G; Brignola S; Sandonà D; Balistreri M; Sabbadin M; Lonardi S; Bergamo F; Mescoli C; Scarpa M; Bao QR; Dei Tos AP; Pucciarelli S; Urso ELD; Fassan M
Pathol Res Pract; 2023 Mar; 243():154366. PubMed ID: 36774759
[TBL] [Abstract][Full Text] [Related]
6. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors.
Mestrallet G; Brown M; Bozkus CC; Bhardwaj N
Front Immunol; 2023; 14():1210164. PubMed ID: 37492581
[TBL] [Abstract][Full Text] [Related]
7. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
Konstantinopoulos PA; Luo W; Liu JF; Gulhan DC; Krasner C; Ishizuka JJ; Gockley AA; Buss M; Growdon WB; Crowe H; Campos S; Lindeman NI; Hill S; Stover E; Schumer S; Wright AA; Curtis J; Quinn R; Whalen C; Gray KP; Penson RT; Cannistra SA; Fleming GF; Matulonis UA
J Clin Oncol; 2019 Oct; 37(30):2786-2794. PubMed ID: 31461377
[TBL] [Abstract][Full Text] [Related]
9. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status.
de Freitas D; Aguiar FN; Anton C; de Almeida DC; Bacchi CE; Carvalho JP; Carvalho FM
Heliyon; 2023 Jun; 9(6):e17495. PubMed ID: 37408903
[TBL] [Abstract][Full Text] [Related]
11. Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma.
Perna C; Navarro A; Ruz-Caracuel I; Caniego-Casas T; Cristóbal E; Leskelä S; Longo F; Caminoa A; Santón A; Ferreiro R; Pizarro D; Palacios-Berraquero ML; Palacios J
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435234
[TBL] [Abstract][Full Text] [Related]
12. A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma.
Luey N; Toon CW; Sioson L; Clarkson A; Watson N; Cussigh C; Kedziora A; Pincott S; Pillinger S; Evans J; Percy J; Engel A; Schnitzler M; Gill AJ
PLoS One; 2014; 9(8):e106105. PubMed ID: 25153715
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair deficiency as a prognostic factor in mucinous colorectal cancer.
Andrici J; Farzin M; Sioson L; Clarkson A; Watson N; Toon CW; Gill AJ
Mod Pathol; 2016 Mar; 29(3):266-74. PubMed ID: 26769140
[TBL] [Abstract][Full Text] [Related]
14. Small Bowel Adenocarcinoma Frequently Exhibits Lynch Syndrome-associated Mismatch Repair Protein Deficiency But Does Not Harbor Sporadic MLH1 Deficiency.
Xia M; Singhi AD; Dudley B; Brand R; Nikiforova M; Pai RK
Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):399-406. PubMed ID: 27258561
[TBL] [Abstract][Full Text] [Related]
15. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
[TBL] [Abstract][Full Text] [Related]
16. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
Kather JN; Halama N; Jaeger D
Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
[TBL] [Abstract][Full Text] [Related]
17. High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer.
Guo J; Tang B; Fu J; Zhu X; Xie W; Wang N; Ding Z; Song Z; Yang Y; Xu G; Xiao X
Cell Oncol (Dordr); 2024 Apr; 47(2):573-585. PubMed ID: 37847338
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency.
Yuan L; Chi Y; Chen W; Chen X; Wei P; Sheng W; Zhou X; Shi D
Int J Clin Exp Med; 2015; 8(11):20988-1000. PubMed ID: 26885030
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
Atwal A; Snowsill T; Dandy MC; Krum T; Newton C; Evans DG; Crosbie EJ; Ryan NAJ
Int J Cancer; 2022 Nov; 151(9):1626-1639. PubMed ID: 35792468
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.
Pasanen A; Loukovaara M; Bützow R
Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
